Health Industry Manufacturers Association (HIMA) urges revamp of Medicare policies
This article was originally published in Clinica
Medicare should pay for costs of care associated with medical device clinical trials approved by the FDA, recommends industry association HIMA. The current practice to deny reimbursement for care involving a device not approved for marketing "has a tragic consequence of delaying and, in some cases, denying Medicare beneficiaries access to the very innovations that are helping other patients lead longer, more productive lives", says HIMA executive vice-president Ted Mannen.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.